s

Protocol: PK Bridging ELISA for Use with Anti-Elotuzumab Antibodies

Protocol: PK Bridging ELISA for Use with Anti-Elotuzumab Antibodies

Pharmacokinetic (PK) Bridging ELISA: For Use with Anti-Elotuzumab Monoclonal Antibodies Catalog TZA0115 with TZA0116/TZA0116P

This method provides a procedure for carrying out a PK ELISA with Anti-Elotuzumab Antibodies, TZA0115 (capture antibody) and HRP-conjugated TZA0116/TZA0116P (detection antibody), using elotuzumab for the standard curve. The method should always be used in conjunction with product and batch-specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.


Reagents

BSA (Sigma-Aldrich, A7906)
HISPEC Assay Diluent (BUF049)
Human Serum (Sigma-Aldrich, H4522)
SpyCatcher Reagents (e.g., TZC002P)
Contact us to discuss suitable options
Phosphate buffered saline (PBS)
136 mM NaCl
2.68 mM KCl
8.1 mM Na2HPO4
1.46 mM KH2PO4
PBST
PBS with 0.05% Tween 20 (Merck Millipore, 817072)
QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, 15169)

Materials

384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, 10395991)
Fluorescence plate reader
96-well plates can be used instead of 384-well plates (black, flat-bottom wells), for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, 437111). For the 96-well format, use 100 μL (instead of 20 μL) of antigen, antibodies, or substrate and 300 μL for the blocking step.

Method

  1. Prepare the capture Anti-Elotuzumab Antibody TZA0115 (AbD60179ad) at 1 µg/mL in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µL per well of the prepared capture antibody, and incubate overnight at 4°C.
  2. If using TZA0116P (AbD60184pap) for detection, proceed to step 3. If using TZA116 (AbD60184ad) for detection, prepare the detection anti-elotuzumab antibody: couple TZA116 (AbD60184ad) to a suitable SpyCatcher reagent (e.g., TZC002P) using the appropriate coupling protocol. 
  3. Wash the microtiter plate five times (5x) with PBST.
  4. Block the microtiter plate by adding 100 µL 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
  5. Wash the microtiter plate 5x with PBST.
  6. For the standard curve, prepare a dilution series of elotuzumab in 10% human serum in PBST in triplicate. Final concentration of elotuzumab should cover the range from 0.008 ng/mL to 32,000 ng/mL. Include a zero elotuzumab concentration as the background value.
  7. Add 20 µL of elotuzumab dilution per well (in triplicate for each standard recommended). Add 20 µL of each test sample to the other wells (in triplicate for each sample recommended). Incubate for 1 hr at RT.
  8. Wash the microtiter plate 5x with PBST.
  9. To each well, add 20 µL of (Bi)SpyCatcher:HRP-coupled detection Anti-Elotuzumab Antibody TZA116 (AbD60184ad) or HRP-conjugated detection TZA0116P (AbD60184pap) at 0.5 µg/mL in HISPEC Assay Diluent. Incubate for 1 hr at RT. 
  10. Wash the microtiter plate 10x with PBST.
  11. Add 20 µL QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.